Displaying One Session

Time
10:30 - 12:00

Welcome and introduction (ID 4714)

Targeting the undruggable: what we know about KRAS-mutant NSCLC (ID 4715)

Harnessing the power of biomarkers to treat NSCLC (ID 4716)

Expanding treatment options for KRAS G12C-mutant NSCLC patients (ID 4717)

Future perspectives: Panel discussion (ID 4718)

Summary and close (ID 4719)